KXAN's hour-long ‘Undocumented' special highlights investigative team's deportation-related discoveries
Undocumented: Texas' immigration impact in a new Trump era
Under President Donald Trump's renewed administration, Texas has emerged as a key frontline in the push for aggressive immigration enforcement. Texas residents – regardless of immigration status – feel the ripple effects in the economy, schools, healthcare systems, courts and public safety services.
To better understand these challenges, KXAN spent the first 100 days of Trump's second term investigating this topic, crowdsourcing for stories and interviews, and compiling a comprehensive project about the real-life consequences of related policies and proposals. Take a closer look at the reports in this special below:
Dozens of Texas police agencies sign 287(g) agreements with ICE
Employers who hire undocumented workers are rarely prosecuted
Some school districts see an initial dip in attendance at the onset of raids
The state collects patients' citizenship status data during hospital visits
Vacancies, political factors surrounding immigration lead to long legal waits
KXAN Investigates Podcast: Central Texas mom fights for daughter's citizenship
The following KXAN staff members contributed to this special: Digital Data Reporter/Producer Christopher Adams, Director Joy-Serene Adams, Senior Graphic Artist Chris Ayers, Senior Investigative Producer David Barer, Photojournalist Jordan Belt, Investigative Photojournalist Richie Bowes, News Director Haley Cihock, Investigative Reporter Arezow Doost, Graphic Artist Wendy Gonzalez, Investigative Reporter Matt Grant, Photojournalist Tim Holcomb, Investigative Producer Dalton Huey, Senior Director Forest Langlee, Lead Editor Eric Lefenfeld, Investigative Photojournalist Chris Nelson, Digital Special Projects Developer Robert Sims, Director Stephanie Soto, Investigative Reporter Avery Travis, Investigative Intern Talisa Treviño, Investigative Reporter Kelly Wiley, Digital Director Kate Winkle and Director Cameron Young.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
26 minutes ago
- CNBC
EU push to protect digital rules holds up trade statement with U.S., FT reports
The European Union is trying to prevent the United States from targeting the bloc's digital rules as both sides work through the final details of a delayed statement to formalize a trade deal reached last month, the Financial Times reported on Sunday. EU officials said disagreements over language relating to "non-tariff barriers," which the U.S. said include the digital rules, are among the reasons for the hold-up of the statement, the newspaper said. Reuters could not immediately verify the report. The European Union, the White House and the State Department did not immediately respond to a request for comment. The statement had originally been expected days after the July announcement by EU President Ursula von der Leyen and U.S. President Donald Trump, according to FT. The July deal imposed a 15% import tariff on most EU goods - half the initially threatened rate - and helped avert a broader trade war between the two allies, who together account for nearly a third of global trade. The U.S. wanted to keep the door open for possible concessions on the EU's Digital Services Act (DSA), which Washington says stifles free speech and imposes costs on U.S. tech companies, according to FT, which added that the commission has said that relaxing these rules is a red line. The EU's DSA is a landmark law meant to make the online environment safer and fairer by compelling tech giants to do more to tackle illegal content, including hate speech and child sexual abuse material. The commission had anticipated that Trump would sign an executive order by August 15 to cut tariffs on EU car exports to the U.S. from 27.5% to 15%. However, a U.S. official signaled that this would be delayed until the joint statement was finalized, according to FT.
New York Times
26 minutes ago
- New York Times
China's Biotech Is Cheaper and Faster
Just outside of Shanghai, in the city of Wuxi, China is building its future of medicine — a booming biotechnology hub of factories and laboratories where global pharmaceutical companies can develop and manufacture drugs faster and cheaper than anywhere else. Amid the Trump administration's tariffs on China, I figured manufacturing hubs like this one would be wracked with anxiety. But when I visited Wuxi in April, government officials insisted that its research hub was flourishing. They were proud to tell me about their superstar labs and companies that are continuing to thrive. The fact that Chinese biotechnology stocks have surged over 60 percent since January seems to bolster this claim. The city's researchers certainly seemed positioned to be busy for decades. In its quest to dethrone American dominance in biotech, China isn't necessarily trying to beat America at its own game. While the U.S. biotech industry is known for incubating cutting-edge treatments and cures, China's approach to innovation is mostly focused on speeding up manufacturing and slashing costs. The idea isn't to advance, say, breakthroughs in the gene-editing technology CRISPR; it's to make the country's research, development, testing and production of drugs and medical products hyperefficient and cheaper. As a result, China's biotech sector can deliver drugs and other medical products to customers at much cheaper prices, including inexpensive generics. These may not be world-changing cures, but they are treatments that millions of people around the world rely on every day. And as China's reach expands, the world will soon have to reckon with a new leader in biotech and decide how it wants to respond. One such company that embodies the Chinese approach to biotech is Wuxi AppTec. It's a one-stop shop for pharmaceutical research and development, streamlining everything from early-stage drug discovery to young scientist recruitment and medication production. The company, whose clients have included Chinese firms like Innovent and Jiangsu Hengrui, as well as American and European drugmakers like Pfizer, GlaxoSmithKline and AstraZeneca, was involved in, by one estimate, a quarter of the drugs used in the United States, including blockbuster cancer drugs. Though the Chinese government bargains hard with both foreign and domestic pharmaceutical companies to provide products at the right price in exchange for market access, the low prices that Chinese consumers pay are ultimately the result of Chinese biotech companies' ability to test and manufacture drugs at a pace far faster than their American counterparts. So far, American biotech giants don't seem to mind the competition, since their own use of companies like Wuxi AppTec allows them to dedicate more of their money to breakthrough research. Want all of The Times? Subscribe.
Yahoo
32 minutes ago
- Yahoo
US cancels India trade talks scheduled for August, NDTV Profit says
(Reuters) -A planned visit by U.S. trade negotiators to New Delhi from August 25-29 has been canceled, delaying talks on a proposed bilateral trade agreement, Indian business and financial news network NDTV Profit reported on Saturday, citing people familiar with the matter. The current round of negotiations for the proposed bilateral trade agreement is now likely to be deferred to another date, the report said, dashing hopes of some relief before the Aug. 27 deadline for the additional tariff on Indian goods kicks in. Reuters could not immediately verify the report. Earlier this month, U.S. President Donald Trump imposed an additional 25% tariff on Indian goods, citing New Delhi's continued imports of Russian oil in a move that sharply escalated tensions between the two nations. The new import tax, which will come into effect from Aug 27, will raise duties on some Indian exports to as high as 50% - among the highest levied on any U.S. trading partner. Trade talks between New Delhi and Washington collapsed after five rounds of negotiations over disagreement on opening India's vast farm and dairy sectors and stopping Russian oil purchases. India's Foreign Ministry has said the country is being unfairly singled out for buying Russian oil while the United States and European Union continue to purchase goods from Russia. Melden Sie sich an, um Ihr Portfolio aufzurufen.
